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ABSTRACT
Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a 
short time period. The high efficacy and good safety profile of direct-acting antivirals has led 
to consensual recommendations for using interferon-free treatment after liver transplantation. 
However, pegylated interferon may still be required for genotype 3 non-responders. We treated 
a liver graft recipient with grade 1 fibrosis in the biopsy with daclatasvir and sofosbuvir for 
12 weeks. He did not respond and progressed to grade 3 fibrosis. Lacking other options, we 
obtained a sustained virological response with pegylated interferon, ribavirin and sofosbuvir 
for 12 weeks. The combination of pegylated interferon, ribavirin and sofosbuvir is a viable 
option after the failure of direct acting antivirals in economically disadvantaged countries. 
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INTRODUCTION
Chronic Hepatitis C Virus (HCV) infection is one of the most common diagnoses 
in candidates for liver transplantation (LT) throughout the world. HCV relapses 
in more than two thirds of those recipients that still have detectable viremia when 
they are submitted to LT. Furthermore, they have much higher viral loads and an 
accelerated disease course in the setting of immunosuppression1. 
The high efficacy and good safety profile of direct-acting antivirals (DAA) has 
led to consensual recommendations for using interferon-free treatment after LT2-4. 
However, there are very few options for patients who fail to respond to DAA, 
especially in developing countries where newer drugs are not yet available. We 
report the case of DAA failure after LT with successful retreatment using pegylated 
interferon with ribavirin (PR) and sofosbuvir, and review the pertinent literature.
CASE PRESENTATION
We describe the case of a male patient submitted to LT due to hepatocellular 
carcinoma (HCC) and compensated cirrhosis caused by HCV when he was 
67 years old. The HCC had been treated with alcohol injections and was 
completely necrotic on the liver explant. He had failed to respond to treatment 
twice before LT, once with standard interferon and ribavirin and once with PR. On 
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the 17th postoperative month, he began a 48-week course 
of PR. Viremia lowered from 3 million international units 
(IU) to 92 IU at treatment week 12. It was undetectable 
at week 24 and at the end of treatment, but he suffered a 
relapse 6 months later, with a viral load of approximately 
1 million IU. PR caused mild pleural and pericardial 
effusion and mild ascites, leading to the interruption of 
these drugs at week 48 instead of 72. Liver biopsy results 
are shown in Table 1. Four years and 3 months after LT, he 
was treated with daclatasvir and sofosbuvir for 12 weeks 
according to the Brazilians’ public health protocol at that 
time, which restricted treatment duration to 12 weeks for 
all patients. Notwithstanding, post-treatment viral load 
was 580.000 IU. One year after that, a fibroelastogram 
showed a liver stiffness of 9.6 kPa, equivalent to grade 
3 fibrosis. Two different liver ultrasound examinations 
did not disclose any signs of chronic liver disease or 
portal hypertension. The patient then received PR plus 
sofosbuvir for 12 weeks. The viral load fell to 35 IU 
after 4 weeks of treatment. Within 7 weeks, ribavirin had 
to be reduced from 1 g to 500 mg daily, because serum 
hemoglobin fell from 12.8 to 7.6 mg/dL. He received 
two red blood cell transfusions; ribavirin was reduced to 
250 mg per day, which he was able to receive until the 
end of treatment. Viral load was undetectable (less than 
12 IU/mL) 24 weeks after treatment and remained so when 
tested after another year.
DISCUSSION
The benefits of treating HCV relapse after LT have 
been more thoroughly evaluated with interferon. There is 
progression to cirrhosis in more than 20% of patients in 
5 years without treatment , with a minimum decompensation 
rate of 30% in the first year. Sustained virological response 
(SVR) leads to favorable outcome with improvement of 
fibrosis, graft and patient survival and reduced rates of 
decompensated cirrhosis5-8.
DAA have revolutionized HCV treatment by means 
of high efficacy and a favorable safety profile. In Brazil, 
DAA has been provided by the public health system since 
2015. We have only two options available for the treatment 
of genotype 3 HCV: PR plus sofosbuvir or sofosbuvir plus 
daclatasvir, with the possibility of adding ribavirin, for 12 
or 24 weeks. At the time the reported patient was treated, 
there was no recommendation from the Brazilian public 
health system to use ribavirin in all LT patients.
Genotype 3 HCV is associated with fewer treatment 
options, faster rates of progression to fibrosis and lower 
SVR rates, especially in the presence of advanced fibrosis 
or decompensated cirrhosis9. Due to its lower prevalence, 
it was underrepresented in clinical trials, especially those 
that included LT patients10-14.
We have previously published our real-life data on HCV 
treatment after LT with a 12-week course of sofosbuvir 
and daclatasvir, with or without ribavirin. There were 4 
treatment failures in 39 patients (89.7% SVR) and one 
of them is the case reported here. It is worth noticing 
that all failures occurred in the subgroup of 26 patients 
with genotype 3 HCV15. The CUPILT study included 137 
mono-infected HCV LT patients treated with sofosbuvir 
and daclatasvir, with or without ribavirin, but only 15 
patients were genotype 316. Ally-1 Phase 3 trial is currently 
underway and its preliminary results have shown up to 
91% of SVR rates, but genotype 3 was represented by only 
11 of 53 LT recipients treated with a 12-week course of 
sofosbuvir, daclatasvir and ribavirin17.
Considering the accelerated rate of progression to 
fibrosis in these immunocompromised patients, they should 
be treated without delay, using other classes of drugs. 
Current options for retreating DAA-experienced genotype 
3 patients include combinations such as sofosbuvir, 
velpatasvir and voxilaprevir18, glecaprevir and pibrentasvir 
or triple combinations including these drugs19. However, 
these recently released DAA are still unavailable in many 
countries.
Resistance-associated variants (RAVs) are selected 
when treatment with daclatasvir or other nonstructural 
protein 5A (NS5A) inhibitors fails, and they might persist 
for a long time after treatment discontinuation1. RAVs 
can compromise DAA retreatment results with regimens 
that include NS5A inhibitors. On the other hand, the 
Y93H RAV has been shown to increase susceptibility 
to interferon-based therapy in comparison with the Y93 
wild type, favoring interferon-containing regimens in 
these cases20.
Table 1 - Anatomopathological results of liver biopsies. 
Postoperative Time Inflammation Fibrosis Conclusion
6 months Severe (grade 3) Absent Acute hepatitis C
9 months Moderate (grade 2) Mild (grade 1) Chronic hepatitis C Metavir A2F1
48 months Mild (grade 1) Mild (grade 1) Chronic hepatitis C Metavir A1F1
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Unlike NS5A inhibitors such as daclatasvir, sofosbuvir 
is a NS5B polymerase inhibitor with a high genetic barrier 
to resistance. A sofosbuvir and PR combination was 
recommended in EASL and AASLD editions in 2015 
for genotype 3 HCV infection, excluding patients with 
decompensated cirrhosis and LT recipients3,4. The TARGET 
real-life study included a subgroup of 19 patients that 
received PR plus sofosbuvir with 84% SVR, although most 
of them were genotype 1 with no history of LT21. Although 
it is not a currently recommended option after LT, there is a 
large experience with PR treatment in these patients before 
DAAs were available.
The therapeutic success that we obtained in this case is 
relevant, because it shows there is an economically viable 
option for LT patients, in whom the disease can progress 
too rapidly to wait for new drugs to become available in 
countries that cannot afford to distribute the top line DAA 
treatment.
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